Please use this identifier to cite or link to this item:
|Title:||The histone deacetylase inhibitor CBHA inhibits growth of human neuroblastoma xenografts in vivo alone and synergistically with all-trans retinoic acid|
|Citation:||Cancer Research, 2001; 61(9):3591-3594|
|Publisher:||Amer Assoc Cancer Research|
|Dennis C. Coffey, Martha C. Kutko, Richard D. Glick, Lisa M. Butler, Glenn Heller, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon, and Michael P. La Quaglia|
|Abstract:||Histone deacetylase inhibitors (HDACIs) inhibit the growth of a variety of transformed cells in culture. We demonstrated previously that the hybrid-polar HDACI m-carboxycinnamic acid bis-hydroxamide (CBHA) induces apoptosis of human neuroblastoma in vitro and is effective in lower doses when combined with retinoids. The current study investigates the effect of CBHA on the growth of human neuroblastoma in vivo, both alone and in combination with all-trans retinoic acid (atRA), using a severe combined immunodeficiency-mouse xenograft model. CBHA (50, 100, and 200 mg/kg/day) inhibited growth of SMS-KCN-69n tumor xenografts in a dose-dependent fashion, with 200 mg/kg CBHA resulting in a complete suppression of tumor growth. The efficacy of 50 and 100 mg/kg CBHA was enhanced by the addition of 2.5 mg/kg atRA. This dose of atRA was ineffective when administered alone. Treatment was accompanied by mild weight loss in all groups except the lowest dose of CBHA. Our results suggest HDACIs alone or combined with retinoids may have therapeutic utility for neuroblastoma.|
|Keywords:||Tumor Cells, Cultured|
Antineoplastic Combined Chemotherapy Protocols
Xenograft Model Antitumor Assays
Dose-Response Relationship, Drug
Histone Deacetylase Inhibitors
|Description:||© 2001 American Association for Cancer Research|
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.